

Publications: 10/1/19 – 9/30/20

1. Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, **Beckwith CG**, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. *BMC Infectious Diseases* (2019) 19:913. <https://doi.org/10.1186/s12879-019-4443-z>
2. Uhrig Castonguay BJ, Cressman AE, Kuo I, Patrick R, Trezza C, Cates A, Olsen H, Peterson J, Kurth A, Bazerman LB, **Beckwith CG**. The Implementation of a Text Messaging Intervention to Improve HIV Continuum of Care Outcomes Among Persons Recently Released From Correctional Facilities: Randomized Controlled Trial. *JMIR Mhealth Uhealth* 2020;8(2):e16220. DOI: [10.2196/16220](https://doi.org/10.2196/16220).
3. Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, **Beckwith CG**, Chander G, Chandler R, Christopoulos K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews C, Mauer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load. *Clinical Infectious Diseases*. 2020; 70 (5): 867-74.
4. Assoumou SA, Paniagua SM, Linas BP, Wang J, Samet JH, Hall J, White LF, **Beckwith CG**. Rapid vs. Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial. *Journal of Infectious Diseases* 2020; accepted for publication March 30, 2020. In press.
5. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, **Beckwith CG**, **Chan PA**, **Mylonakis E**. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. *Obesity (Silver Spring)*. 2020 Jul;28(7):1200-1204. doi: 10.1002/oby.22859. Epub 2020 Jun 12. PMID: 32352637; PMCID: PMC7267224
6. Byrd K, **Beckwith C**, **Garland J**, **Johnson J**, Aung S, **Cu-Uvin S**, **Farmakiotis D**, **Flanigan T**, **Gillani F**, Macias-Gil R, **Mileno M**, **Ramratnam B**, **Rybak N**, **Sanchez M**, **Tashima K**, **Mylonakis E**, **Kantor R**. SARS-CoV-2 and HIV Coinfection: Clinical Experience from Rhode Island, United States. *Journal of the International AIDS Society J Int AIDS Soc*. 2020 Jul; 23(7):e25573. Doi:10.1002/jia2.25573. PMID 32657527
7. Nowotny KM, Zielinski MJ, Stringer KL, Pugh T, Wu E, Metsch LR, El-Bassel N, Nunn AS, **Beckwith CG**. Training the Next Generation of Researchers Dedicated to Improving Health Outcomes for Justice-Involved Populations. *American Journal of Public Health*. 2020 Vol 110; S1: S18-S20.
8. Wurcel AG, Dauria E, Zaller N, Nijhawan A, **Beckwith C**, Nowotny K, Brinkley-Rubinstein L. Spotlight on jails: COVID-19 mitigation polices needed now. *Clinical Infectious Diseases* 2020. Published online 28 March 2020. <https://doi.org/10.1093/cid/ciaa346>.
9. Assoumou SA, Paniagua SM, Linas BP, Wang J, Samet JH, Hall J, White LF, **Beckwith CG**. Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification

Publications: 10/1/19 – 9/30/20

Treatment Center: A Randomized Trial. *J Infect Dis.* 2020 Sep 2;222(Supplement_5):S376-S383. doi: 10.1093/infdis/jiaa162. PMID: 32877557.

10. Donnelly JP, Chen SC, Kauffman CA, **Caliendo AM**, Pappas PG. Revision and Update of the Consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis.* 2019 Dec 5:ciz1008. doi: 10.1093/cid/ciz1008. Online ahead of print.
11. Kitzman H, Olds DL, Knudtson MD, Cole R, Anson E, Smith JA, Fishbein D, DiClemente R, Wingood G, **Caliendo AM**, Hopfer C, Miller T, Conti G. Prenatal and infancy nurse home visiting and 18-year outcomes of a randomized trial. *Pediatrics.* 2019 Dec;144(6):e20183876. doi: 10.1542/peds.2018-3876. Epub 2019 Nov 20.
12. Hayden RT, Tang L, Su Y, Cook L, Gu Z, Jerome K, Boonyaratanakornkit J, Sam S, Pounds S and **Caliendo AM**. Impact of fragmentation on Commutability of Epstein-Barr and cytomegalovirus quantitative standards. *J Clin Micro.* 2019 Dec 23;58 (1):e00888-19. doi:10.1128/JCM.00888-19. Print 2019 Dec 23.
13. Hanson KE, Azar MM, Banerjee R, Chou A, Colgrove RC, Ginocchio CC, Hayden KM, Mark Holodiny M, Jain S, Koo S, Levy J, Timbrook TT and **Caliendo AM**, for the Diagnostics Committee of the Infectious Diseases Society of America (IDSA). Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's Diagnostics Committee. *Clin Infect Dis.* 2020 May 5:ciaa508. doi: 10.1093/cid/ciaa508. Online ahead of print.
14. Kalichman SC, Eaton LA, Berman M, Kalichman MO, Katner H, Sam SS, **Caliendo AM**. Intersecting Pandemics: Impact of SARS-CoV-2 (COVID-19) Protective Behaviors on People Living With HIV, Atlanta, Georgia. *J Acquir Immune Defic Syndr.* 2020;85:66-72. doi: 10.1097/QAI.0000000000002414. Online ahead of print.
15. Hanson KE, **Caliendo AM**, Arias CA, Englund JA, Lee MJ, Loeb M, Patel R, El Alayli A, Kalot MA, Falck-Ytter Y, Lavergne V, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. *Clin Infect Dis.* 2020 Jun 16:ciaa760. doi: 10.1093/cid/ciaa760. Online ahead of print. PMID: 32556191
16. Sultan S, Siddique SM, Altayar O, **Caliendo AM**, Davitkov P, Feuerstein JD, Francis D, Inadomi J, Lim JK, Falck-Ytter Y, Mustafa RA on behalf of the AGA. AGA Institute Rapid Review and Recommendations on the role of pre-procedure SARS-CoV2 testing and endoscopy. *Gastroenterology* (2020), doi:<https://doi.org/10.1053/j.gastro.2020.07.043>.
17. Sowemimo-Coker G, Lee AJ, Montgomery MC, Nunn AS, van den Berg JJ, **Chan PA**. Insurance Status and Access to Sexual Health Services Among At-Risk Men: A Qualitative Study. *J Assoc Nurses AIDS Care.* 2019 Sep-Oct;30(5):e122-e131.

Publications: 10/1/19 – 9/30/20

18. Goedel WC, Nunn AS, **Chan PA**, Duncan DT, Biello KB, Safren SA, Marshall BDL. A shot at equity? Addressing disparities among Black MSM in the coming era of long-acting injectable preexposure prophylaxis. *AIDS*. 2019 Nov 1;33(13):2110-2112.
19. **Chan PA**, Goedel WC, Nunn AS, Sowemimo-Coker G, Galárraga O, Prospero M, Patel R, Mena L, Montgomery MC, Marshall BDL. Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation. *AIDS Patient Care STDS*. 2019 Oct;33(10):434-439.
20. Ellison J, van den Berg JJ, Montgomery MC, Tao J, Pashankar R, Mimiaga MJ, **Chan PA**. Next-Generation HIV Pre-Exposure Prophylaxis Preferences Among Men Who Have Sex with Men Taking Daily Oral Pre-Exposure Prophylaxis. *AIDS Patient Care STDS*. 2019 Oct 11.
21. Goedel WC, **Chan PA**, King MRF, Prospero MCF, Marshall BDL, Galárraga O. Cost-effectiveness of a statewide pre-exposure prophylaxis program for gay, bisexual, and other men who have sex with men. *R I Med J* (2013). 2019; 102(9): 36–39.
22. **Chan PA**, Seiler N, Chu CT. Leveraging Medicaid to Enhance Preexposure Prophylaxis Implementation Efforts and Ending the HIV Epidemic. *Am J Public Health*. 2020 Jan;110(1):65-66.
23. Montgomery MC, Alholm Z, Almonte A, Sykes KJ, Rudolph G, Cusick B, Castello L, Sowemimo-Coker G, Tang I, Haberlack S, **Chan PA**. A cross-sectional evaluation of HIV testing practices among women in the rural Dominican Republic. *BMC Womens Health*. 2020 Feb 7;20(1):21.
24. Nunn AS, Goedel WC, Gomillia CE, Coats CS, Patel RR, Murphy MJ, Chu CT, **Chan PA**, Mena LA. False information on PrEP in direct-to-consumer advertising. *Lancet HIV*. 2020 Feb 4.
25. Raifman J, Charlton BM, Arrington-Sanders R, **Chan PA**, Rusley J, Mayer KH, Stein MD, Austin SB, McConnell M. Sexual Orientation and Suicide Attempt Disparities Among US Adolescents: 2009-2017. *Pediatrics*. 2020 Feb 10.
26. Tang E, Paiva KJ, Pytel-Parenteau DL, Maynard MA, **Chan PA**, Lu S. Evaluation of BioPlex 2200 Syphilis Total with Automated Rapid Plasma Reagin (RPR): Experience from a Tertiary Medical Center. *Sex Transm Dis*. 2020 Feb 18.
27. Brinkley-Rubinstein L, Crowley C, Montgomery MC, Peterson M, Zaller N, Martin R, Clarke J, Dubey M, **Chan PA**. Interest and Knowledge of HIV Pre-Exposure Prophylaxis in a Unified Jail and Prison Setting. *J Correct Health Care*. 2020 Feb 27:1078345819897405.
28. Patel RR, Curoe KA, **Chan PA**. Undetectable Equals Untransmittable: A Game Changer for HIV Prevention. *Clin Chem*. 2020 Mar 1;66(3):406-407.

Publications: 10/1/19 – 9/30/20

29. Bonnewell J, Magaziner S, Fava JL, Montgomery MC, Almonte A, Carey M, **Chan PA**. A survey of syphilis knowledge among medical providers and students in Rhode Island. *SAGE Open Med*. 2020 Feb 4;8:2050312120902591.
30. Van Der Pol B, Waites KB, Xiao L, Taylor SN, Rao A, Nye M, Chavoustie S, Ermel A, Kaplan C, Eisenberg D, **Chan PA**, Mena L, Pacheco S, Krishnamurthy S, Mohan R, Bertuzis R, McGowin CL, Arcenas R, Marlowe EM. Mycoplasma genitalium detection in urogenital specimens from symptomatic and asymptomatic men and women using the cobas TV/MG test. *J Clin Microbiol*. 2020 Mar 25.
31. Goedel WC, Mimiaga MJ, King MRF, Safren SA, Mayer KH, **Chan PA**, Marshall BDL, Biello KB. Potential Impact of Targeted HIV Pre-Exposure Prophylaxis Uptake Among Male Sex Workers. *Sci Rep*. 2020 Mar 27;10(1):5650.
32. Raifman J, Nocka K, Galárraga O, Wilson IB, Crowley C, Tao J, Napoleon S, Marak T, **Chan PA**. Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data. *Ann Epidemiol*. 2020 Mar 26.
33. Rogers BG, Coats CS, Adams E, Murphy M, Stewart C, Arnold T, **Chan PA**, Nunn A. Development of Telemedicine Infrastructure at an LGBTQ+ Clinic to Support HIV Prevention and Care in Response to COVID-19, Providence, RI. *AIDS Behav*. 2020 Apr 29.
34. Napoleon SC, Maynard MA, Almonte A, Cormier K, Bertrand T, Ard KL, **Chan PA**. Considerations for STI Clinics during the COVID-19 pandemic. *Sex Transm Dis*. 2020 Apr 29.
35. Rogers BG, Arnold T, Schierberl Scherr A, Strong SH, Holcomb R, Daley Ndoye C, Pinkston M, **Chan PA**. Adapting Substance Use Treatment for HIV Affected Communities During COVID-19: Comparisons Between a Sexually Transmitted Infections (STI) Clinic and a Local Community Based Organization. *AIDS Behav*. 2020 May 27.
36. Murphy M, Howe K, Marak T, Bertrand T, Maynard M, Ndoye CD, Joseph R, Fingerut J, **Chan PA**. Public Health Approaches Toward Eliminating Hepatitis C Virus in Rhode Island. *R I Med J* (2013). 2020 Jun 1;103(5):22-25.
37. Weng CH, Saal A, **Chan PA**. Differences in Clinical Characteristics of Covid-19 in Hispanic/Latino Population. *Transbound Emerg Dis*. 2020 Jun 8.
38. Weng CH, Saal A, Butt WWW, **Chan PA**. Characteristics and Clinical Course and Outcome of COVID-19 in Hispanic/Latino Patients in a Community Setting: A Retrospective Cohort Study. *J Med Virol*. 2020 Jun 19.
39. Weng CH, Saal A, Butt WW, Bica N, Fisher JQ, Tao J, **Chan PA**. Bacillus Calmette-Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study. *Epidemiol Infect*. 2020 Jul 9:1-9.

Publications: 10/1/19 – 9/30/20

40. Weng CH, Saal A, **Chan PA**. High Prevalence of SARS-CoV-2 Infection Among the Uninsured Hispanic/Latino Population: a Retrospective Cohort Study. *J Gen Intern Med*. 2020 Jul 14.
41. Wray TB, **Chan PA**, Klausner JD, Mena LA, Brock JB, Simpanen EM, Ward LM, Chrysovalantis S. eTest: a limited-interaction, longitudinal randomized controlled trial of a mobile health platform that enables real-time phone counseling after HIV self-testing among high-risk men who have sex with men. *Trials*. 2020 Jul 16;21(1):654.
42. Tao J, Montgomery MC, Chu CT, Sosnowy C, Almonte A, Goedel WC, Silva ES, Reisopoulos A, Marshall SA, Zaller ND, Rogers BG, Nunn AS, Marshall BDL, **Chan PA**. HIV Pre-Exposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men Only and Men Who Have Sex with Both Men and Women. *AIDS Patient Care STDS*. 2020 Jul 17.
43. Paiva KJ, Grisson RD, **Chan PA**, Huard RC, **Caliendo AM**, **Lonks JR**, King E, Tang EW, Pytel-Parenteau DL, Nam GH, Yakirevich E, Lu S. Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays. *J Med Virol*. 2020 Jul 25.
44. Lurie MN, Silva J, Yorlets RR, Tao J, **Chan PA**. COVID-19 epidemic doubling time in the United States before and during stay-at-home restrictions. *J Infect Dis*. 2020 Aug 1.
45. Sosnowy C, Tao J, Nunez H, Montgomery MC, Ndoye CD, Biello K, Mimiaga MJ, Raifman J, Murphy M, Nunn A, Maynard M, **Chan PA**. Awareness and use of HIV pre-exposure prophylaxis among people who engage in sex work presenting to a sexually transmitted infection clinic. *Int J STD AIDS*. 2020 Aug 4.
46. Is the juice worth the squeeze? Rapid identification and antimicrobial susceptibility testing using the Accelerate Pheno™ system.
Chapin K, **Rogers R**, **Cunha CB**, Zannini A, Bobenchik A, Kearney M.
Presented: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 2019
47. Cunha BA, **Cunha CB**: Pharmacokinetic Considerations in Selecting Optimal Antibiotic Therapy for *Mycoplasma pneumoniae* Encephalitis. *European Journal of Clinical Microbiology & Infectious Diseases*: 38:631-635, 2019
48. Weiss Z, **Cunha CB**, Chambers A, Carr A, Rochat C, Raglow-Defranco M, Parente D, Angus A, **Mermel L**, Sivaprasad L, Chapin K. Impact of rapid respiratory multiplex molecular assay turnaround time on antibiotic use in hospitalized adult patients with acute respiratory tract infection. *Journal of Clinical Microbiology*: 57:e00861-19, 2019
49. Blum, S, Cunha BA, **Cunha CB**. Lack of a Pharmacokinetic Basis of Weight based Dosing and Intraoperative Re-dosing in Obese Patients with Cefazolin Surgical

Publications: 10/1/19 – 9/30/20

Prophylaxis: Implications for Antibiotic Stewardship. *Surgical Infections*. 20:439-443, 2019

50. **Cunha CB**. Viridans Streptococci, Nutritionally Variant Streptococci, and Groups C and G Streptococci.
In: Bennett JE, Dolin R, Blaser MJ (eds.): *Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases*.
Elsevier, New York, 2019
51. Cunha BA, **Cunha CB**. Viral and Mycoplasmal Pneumonias.
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2019*
Elsevier, New York, 2019
52. **Cunha CB**, Cunha BA. Babesiosis.
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2019*
Elsevier, New York, 2019
53. Cunha BA, Hage JE, Schoch PE, **Cunha CB**, Bottone EJ, Torres DC.
Overview of Antimicrobial Therapy.
In: Cunha CB, Cunha, BA (eds.): *Antibiotic Essentials* (16th Edition).
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2019
54. Cunha BA, Bruschi JL, Nichols RL, Papanicolaou G, Hage JE, Koff RS,
Rex JH, Cleri DJ, **Cunha CB**, Fischer SA, Schlossberg D.
Empiric Therapy Based on Clinical Syndrome.
In: Cunha CB, Cunha BA (eds.): *Antibiotic Essentials* (16th Edition).
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2019
55. Cunha BA, Torres DC, Hage JE, Kubiak DW, Mickail N, Gran A, Munoz-
Gomez S, **Cunha CB**, Rex JH, Kaplan MH, Parente DG, Lorenzo M
Antimicrobial Drug Summaries.
In: Cunha CB, Cunha BA (eds.): *Antibiotic Essentials* (16th Edition).
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2019
56. **Cunha CB**, Opal SM. What Strategies Can be Used to Optimize Antibiotic
Use in the Critically Ill?
In: Deutschman C, Neligan P (eds.): *Evidence-Based Practice of Critical Care*
(3rd Edition). Elsevier, Philadelphia, 2019
57. **Cunha CB**, Cunha BA, (**Editors**), *Antibiotic Essentials* (16th Edition).
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2019
58. Ermel A, Tonui P, Titus M, Tong Y, Wong N, Ong'echa J, Muthoka K, Kiptoo S, Moormann
A, Hogan J, Mwangi A, **Cu-Uvin S**, Loehrer PJ, Orang'o O, Brown D. [A cross-sectional
analysis of factors associated with detection of oncogenic human papillomavirus in human](#)

Publications: 10/1/19 – 9/30/20

[immunodeficiency virus-infected and uninfected Kenyan women.](#) (2019) *BMC Infect Dis.* Apr 27;19(1):352. PMID: 31029097

59. Restar AHJ, Chan RCH, Adia A, Quilantang MI, Nazareno J, Hernandez L, **Cu-Uvin S**, Operario D. Prioritizing HIV Services for Transgender Women and Men who have Sex with Men in Manila, Philippines: An Opportunity for HIV Provider Interventions. (2019) *J Assoc Nurses AIDS Care.* Oct 4. Doi: 10.1097/JNC.000000000000131. PMID: 31592803
60. Restar AJ, Santamaria EK, Adia A, Nazareno J, Chan R, Lurie M, Sandfort T, Hernandez L, **Cu-Uvin**, Operario D. Gender affirmative HIV care framework; Decisions on feminizing hormone therapy (FHT) and antiretroviral therapy (ART) among transgender women. (2019) *PLoS One.* Oct 21; 14(10): e0224133. PMID: 31634378. PMCID: PMC6802834
61. Mehta N, Orango O, Itsura P, Tonui P, Bussmann H, Bogers JP, Liu T, **Cu-Uvin S**. Loop Electrosurgical Excision Procedure Treats Cervical Intraepithelial Neoplasia 2/3 among HIV- and HIV+ Women in Kenya. (2020) *J Low Genit Tract Dis.* Jan: 245(1):21-6. PMID: 31860571
62. Peter IM, Deraney RN, Orango O, Philip T, Rosen B, **Cu-Uvin S**. Radical Hysterectomy for operable early cervical cancer in HIV-positive and HIV-negative women in western Kenya. (2020) *Int J Gynaecol Obstet.* Mar; 148(3):403-4. PMID: 31628862
63. Restar AJ, Adia A, Nazareno J, Hernandez L, Sandfort T, Lurie M, **Cu-Uvin S**, Operario D. Barriers and facilitators to uptake of condoms among Filipinz transgender women and cisgender men who have sex with men: A situation socio-ecological perspective. (2020) *Glob Public Health.* Apr; 15(4):520-31. PMID: 31630622. PMCID: PMC7093239
64. **D'Agata EMC**, **Geffert SF**, McTavish R, Wilson F, Cameron C. Acquisition of multidrug-resistant organisms in the absence of antimicrobial exposure: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2019;40:1129-134.
65. Loizeau AJ, **D'Agata EMC**, ML Shaffer, LC Hanson, RA Anderson, Tsai, T, Habtemariam DA, Bergman EH, Carroll RP, Cohen SM, Scott EM, Stevens E, Whyman JD. The Trial to Reduce Antimicrobial Use in Nursing Home Residents with Alzheimer's Disease and other Dementias: Protocol of a Hybrid Efficacy-Effectiveness Cluster Randomized Clinical Trial. *Trials* 2019;20:594-608.
66. Araos R, Battaglia T, Ugalde JA, Rojas-Herrera M, Blaser MJ, **D'Agata EMC**. Fecal microbiome characteristics and the resistome associated with acquisition of multidrug-resistant organisms among elderly subjects. *Front Microbiol* 2019 Sep 27;10:2260. doi: 10.3389/fmicb.2019.02260.
67. Shaffer M, **D'Agata EMC**, Habtemariam D, Mitchell S. Covariate-constrained randomization for cluster randomized trials in the long-term care setting: Application to the TRAIN-AD trial. *Contemporary Clinical Trials Communications.* 2020; 18, Article 100558.

Publications: 10/1/19 – 9/30/20

68. Rowan-Nash AD, Araos R, **D'Agata EMC**, Belenky P. Antimicrobial Resistance Gene Prevalence in a Population of Patients With Advanced Dementia Is Related to Specific Pathobionts. *iScience* 2020;23:100905. doi: 10.1016/j.isci.2020.100905. Epub 2020 Feb 1.
69. **Farmakiotis D**. The human microbiome and checkpoint inhibition: potential benefits from antibiotic stewardship. *Clin Infect Dis* 2020; 71(3): 701-2. PMID: 31608406.
70. Naeem S, Gohh R, Bayliss G, Cosgrove C, **Farmakiotis D**, Merhi B, Morrissey P, Osband A, Bailey JA, Sweeney J, **Rogers R**. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. *Transpl Infect Dis*. 2020 Aug 19:e13451. doi: 10.1111/tid.13451. Epub ahead of print. PMID: 32815238; PMCID: PMC7460867.
71. Lerner A, **Farmakiotis D**. CMV cell-mediated immunity assays: Focus on CD4+ cells. *Am J Transplant* 2020; 20(80): 2285-6. PMID: 32185870.
72. Higgins AB, **Farmakiotis D**, **Rogers R**, Osband AJ, Seo A, Chen B, Birkenbach MP, Crabb D, Xiao L, Leal S, Waites K, Gohh R, Morrissey P, **Nau GJ**. Hyperammonemia syndrome due to *Ureaplasma urealyticum* in a kidney transplant recipient: a case of disseminated disease from a fluoroquinolone-resistant isolate. *Transpl Infect Dis*; in press. PMID: 32416005.
73. Hsu A, Matera R, Vieira K, Reagan JL, **Farmakiotis D**. Antifungal prophylaxis during 7+3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections. *Support Care Cancer*; in press. PMID: 32435969.
74. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilan MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, **Farmakiotis D**, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer: a cohort study. *Lancet* 2020; 395(10241): 1907-18. PMID: 32473681.

Publications: 10/1/19 – 9/30/20

75. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshov DB, Egan PC, **Farmakiotis D**, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. *Cancer Discov* 2020; in press. PMID: 32699031.
76. Pandita A, Dannheim K, Madhuripan N, Ehsan A, **Farmakiotis D**. Acute necrotizing pneumonia from Herpes Simplex Virus. *Am J Med*; in press. PMID: 32835692.
77. Vale CA, Egan PC, Ingham R, **Farmakiotis D**, Reagan JL. Outcomes associated with antimicrobial use during high dose cytarabine consolidation in acute myeloid leukemia. *Ann Hematol*; in press. PMID: 32870366.
78. Pandita A, Macias-Gil R, **Farmakiotis D**. Call for action: Racial disparities in clinical research. *Clin Infect Dis*; in press. PMID: 32894751.
79. Kobayashi T, Marra AR, Schweizer ML, Ten P, Wu C, Alzunitan M, Salinas J, Siege M, **Farmakiotis D**, Auwaerter P, Healy H, Diekema D. Impact of infectious disease consultation in patients with candidemia: A retrospective study, systematic literature review and meta-analysis. *Open Forum Infect Dis* 2020; 7(9): ofaa270. PMID: 32904995.
80. Tsikala-Vafea M, Cao W, Olszewski AJ, Donahue JE, **Farmakiotis D**. Fatal mucormycosis and aspergillosis in an atypical host: What do we know about mixed invasive mold infections? *Case Rep Infect Dis* 2020: 8812528. PMID: 32908735.
81. **Farmakiotis D**, Weiss Z, Brotherton A, Morrissey PE, Gohh RY, Vieira K, Taylor LE, **Garland JM**. “Successful kidney transplantation in a recipient co-infected with hepatitis C genotype 2 and HIV from a donor infected with hepatitis C genotype 1 in the direct-acting antiviral era.” *Case Reports Hepatol*: 2020. Jan 29;2020:7679147. doi: 10.1155/2020/7679147. PMID: 32082657
82. Tiruneh YM, Li X, Bovell-Ammon B, Iroh P, **Flanigan TP**, Montague BT, **Rich JD**, Nijhawan AE. Falling through the Cracks: Risk Factors for Becoming Lost to IV Care after Incarceration in a Southern Jail. *HIV Care after Incarceration in a Southern Jail*. (2020) *AIDS Behav*. Jan 31. Doi: 10.1007/s10461-020-02803-7. PMID 32006154
83. Aibana O, Dauria E, Kiriazova T, Makarenko O, Bachmaha M, Rybak N, **Flanigan TP**, Petrenko V, Becker AE, Murray MB. Patients’ Perspectives of Tuberculosis treatment challenges and barriers to treatment adherence in Ukraine: A Qualitative Study. (2020) *BMJ Open*. Feb 2: 10(1): e032027. Doi: 10.1136 / bmjopen-2019-032027. PMID: 32014870. PMCID: PMC7044979.

Publications: 10/1/19 – 9/30/20

84. Grein J, Ohmagari N, Shim D, Diaz G, Asperges E, Castagna A, et al., **Flanigan TP**. Compassionate use of Remdesivir for patients with Severe Covid -19. (2020) *N Engl J Med*. Apr. doi: 10.1056/NEJMoa2007016. PMID: 32275812. PMCID: PMC769476
85. Neduzhko O, Postnov O, Sereda Y, Kulchynska R, Bingham T, Myers JJ, **Flanigan T**, Kiriazova T. Modified Antiretroviral Treatment Access Study (MARTAS): A Randomized Controlled Trial of the Efficacy of a Linkage-to-Care Intervention among HIV-positive Patients in Ukraine. (2020) *AIDS Behav*. Apr 24. doi: 10/s10461-020-02873-7.
86. Wang L, Chen R, Weng Q, Lin S, Wang H, Li L, **Fuchs BB**, Tan X, **Mylonakis E**. SPT20 Regulates the Hog1-MAPK pathway and is involved in *Candida albicans* response to hyperosmotic stress. *Front Microbiol*. 2020; 11:213. PMID: 32153525
87. de Alvarenga JA, de Barros PP, de Camargo Ribeiro F, Rossoni RD, Garcia MT, dos Santos Velloso M, Shukla S, **Fuchs BB**, Shukla A, **Mylonakis E**, Junqueira JC. Probiotic effects of *Lactobacillus paracasei* 28.4 to inhibit *Streptococcus mutans* in a gellan-based formulation Probiotics Antimicrob Proteins (in press).
88. Ribeiro FC, Junqueira JC, Dos Santos JD, de Barros PP, Rossoni RD, Shukla S, **Fuchs BB**, Shukla A, **Mylonakis E**. Development of probiotic formulations for oral candidiasis prevention: Gellan gum as a carrier to deliver *Lactobacillus paracasei* 28.4. *Antimicrob Agents Chemother*. 2020; 21:64(6). PMID: 32253208
89. Antoran A, Aparicio-Fernandez L, Pellon A, Buldain I, Martin-Souto L, Rementeria A, Ghannoum MA, **Fuchs BB**, **Mylonakis E**, Hernando FL, Ramirez-Garcia A. The monoclonal antibody Ca37, developed against *Candida albicans* alcohol dehydrogenase, inhibits the yeast in vitro and in vivo. *Sci Rep*. 2020; 10(1):9206. PMID: 32514067
90. Kim SM, Escobar I, Lee K, **Fuchs BB**, **Mylonakis E**, Kim W. Anti-MRSA agent discovery using *Caenorhabditis elegans*-based high-throughput screening. *J Microbiol*. 2020 Jun;58(6):431-444. doi: 10.1007/s12275-020-0163-8. Epub 2020 May 27. PMID: 32462486.
91. Rossoni RD, de Barros PP, Mendonça IDC, Medina RP, Silva DHS, **Fuchs BB**, Junqueira JC, **Mylonakis E**. The Postbiotic Activity of *Lactobacillus paracasei* 28.4 against *Candida auris*. *Front Cell Infect Microbiol*. 2020 Aug 4;10:397. doi: 10.3389/fcimb.2020.00397. PMID: 32850495; PMCID: PMC7417517.
92. Huang X, Pan W, Kim W, White A, Li S, Li H, Lee K, **Fuchs BB**, Zeng K, **Mylonakis E**. *Caenorhabditis elegans* mounts a p38 MAPK pathway-mediated defense to *Cutibacterium acnes* infection. *Cell Microbiol*. 2020 (In press). PMID: 32543022
93. Magalhães TFF, da Silva CM, Dos Santos LBF, Santos DA, Silva LM, **Fuchs BB**, **Mylonakis E**, Martins CVB, de Resende-Stoianoff MA, de Fátima Â. Cinnamyl Schiff bases: synthesis, cytotoxic effects and antifungal activity of clinical interest. *Lett Appl Microbiol*. 2020 Aug 10. doi: 10.1111/lam.13356. Epub ahead of print. PMID: 32777092.

Publications: 10/1/19 – 9/30/20

94. Jéssica Diane dos Santos, Luciana Ruano De Oliveira Fugisaki, Rebeca Previante Medina, Liliana Scorzoni, Mariana De Sá Alves, Patrícia Pimentel De Barros, Felipe Camargo Ribeiro, **Beth Fuchs, Eleftherios Mylonakis**, Dulce Helena Siqueira Silva, Juliana Campos Junqueira. Streptococcus mutans secreted products inhibit Candida albicans induced oral candidiasis. *Frontiers in Microbiology* 2020 (In press).
95. **Garland JM**, Levinson A, **Wing EJ**. Care of Critically ill patients with Human Immunodeficiency Virus. (2020) *Ann Am Thorac Soc*. Jun;17(6): 659-69. PMID:32216642
96. **Garland JM, Flanigan T, Wing EJ**. Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. Wing EJ, Schiffman F (Eds). In *Cecil Essentials of Medicine*. Elsevier, Inc., 2020. 10th edition
97. Choe YJ, Blatt DB, Yalcindag A, **Geffert SF**, Bobenchik AM, Michelow IC. Cryptococcus albidus Fungemia in an Immunosuppressed Child: Case Report and Systematic Literature Review. *J Pediatric Infect Dis Soc*. 2020 Feb 28;9(1):100-105. doi: 10.1093/jpids/piz039. PMID: 31183496.
98. Qadeer F, Shemin D, **Gillani FS, D'Agata EMC**. The rise in gram-negative bacteria causing blood stream infections among maintenance hemodialysis patients. *Kidney Med* 2019;1:144-6.
99. Wang S, Hu YJ, Little P, Wang Y, Chan Q, Zhou X, Moore M, **Harwell JI**. The impact of the National Action Plan on the epidemiology of antibiotic resistance among 352,238 isolates in a tertiary teaching hospital in China from 2015-2018. *Antimicrob Resist Infect Control* 2019;8(22): <https://doi.org/10.1186/s13756-019-0473-y>
100. Prabhu S, **Harwell JI**, Kumarasamy N. Advanced HIV: Diagnosis, treatment and prevention. *Lancet HIV* 2019 [http://dx.doi.org/10.1016/S2352-3018\(19\)30189-4](http://dx.doi.org/10.1016/S2352-3018(19)30189-4)
101. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, **Harwell JI**, Magambo K, Middlecote C, Caldwell B, Katureebe C, Namuwenge N, Atugonza R, Musoke A, Musinguzi J. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study. *PLoS One*. 2020 May 27;15(5):e0232419. doi: 10.1371/journal.pone.0232419.
102. CE Boeke, S Khan, F Walsh, A Hettema, C Lejeune, D Spiegelman, V Okello, **Ji Harwell, S Mazibuko, T Bärnighausen**. Universal test and treat in relation to HIV disease progression: Results from a stepped-wedge trial in Eswatini. *HIV Med* 2020 (in press).
103. **Harwell JI**. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO. <https://www.who.int/publications/i/item/9789240008045>
104. Patel KM, **Johnson JE**, Reece R, **Mermel LA**. Babesiosis-associated splenic rupture: A case series from a hyperendemic region. *Clin Infect Dis* 69:1212-1217; 2019.

Publications: 10/1/19 – 9/30/20

105. **Johnson J, Mylonakis E.** *Listeria monocytogenes* and Human Listeriosis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease 9th edition. 2020
106. Parkin NT, Avila-Rios S, Bibby DF, Brumme CJ, Eshleman SH, Harrigan PR, Howison M, Hunt G, Ji H, **Kantor R**, Ledwaba J, Lee ER, Matías-Florentino M, Mbisa JL, Noguera-Julian M, Paredes R, Rivera-Amill V, Swanstrom R, Zaccaro DJ, Zhang Y, Zhou S, Jennings C. Multi-Laboratory Comparison of Next-Generation to Sanger- Based Sequencing for HIV-1 Drug Resistance Genotyping. *Viruses*. 2020 Jun 27;12(7):694. doi: 10.3390/v12070694. PMID: 32605062; PMCID: PMC7411816.
107. Noguera-Julian M, Lee ER, Shafer RW, **Kantor R**, Ji H. Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing. *Viruses*. 2020 Jun 20;12(6):666. doi: 10.3390/v12060666. PMID: 32575676; PMCID: PMC7354622.
108. Ávila-Ríos S, Parkin N, Swanstrom R, Paredes R, Shafer R, Ji H, **Kantor R**. Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. *Viruses*. 2020 Jun 5;12(6):617. doi: 10.3390/v12060617. PMID: 32516949; PMCID: PMC7354449.
109. Ji H, Sandstrom P, Paredes R, Harrigan PR, Brumme CJ, Avila Rios S, Noguera-Julian M, Parkin N, **Kantor R**. Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium. *Viruses*. 2020 May 27;12(6):586. doi: 10.3390/v12060586. PMID: 32471096; PMCID: PMC7354487.
110. Ji H, Parkin N, Gao F, Denny T, Jennings C, Sandstrom P, **Kantor R**. External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. *Viruses*. 2020 May 18;12(5):556. doi: 10.3390/v12050556. PMID: 32443529; PMCID: PMC7291315.
111. Tzou PL, Kosakovsky Pond SL, Avila-Rios S, Holmes SP, **Kantor R**, Shafer RW. Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. *PLoS One*. 2020 Feb 26;15(2):e0225352. doi: 10.1371/journal.pone.0225352. PMID: 32102090; PMCID: PMC7043932.
112. Lee ER, Parkin N, Jennings C, Brumme CJ, Enns E, Casadellà M, Howison M, Coetzer M, Avila-Rios S, Capina R, Marinier E, Van Domselaar G, Noguera-Julian M, Kirkby D, Knaggs J, Harrigan R, Quiñones-Mateu M, Paredes R, **Kantor R**, Sandstrom P, Ji H. Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. *Sci Rep*. 2020 Jan 31;10(1):1634. doi: 10.1038/s41598-020-58544-z. PMID: 32005884; PMCID: PMC6994664.
113. Ludema C, Wilson CM, Michelle A. **Lally MA**, Jacob J. van den Berg JJ, and J. Dennis Fortenberry JD. Prior incarceration associated with missed HIV care visits among young people living with HIV in the US. *AIDS Care*. 2020 Jan 7: 1-5. PMID: 31910666.

Publications: 10/1/19 – 9/30/20

114. Van den Berg JJ, Gamarel KE, Westfall AO, Fortenberry JD, Hosek SG, Wilson CM, **Lally MA**. Transmission Risk Among Youth Living With HIV in the US. *J Adolesc Health* 2020 March 10. PMID 32169529.
115. Kalligeros M, Shehadeha F, Atallaa E, Mylonaa EK, Aung S, Panditaa A, **Larkin J, Sanchez M, Touzard-Romo F**, Brotherton A, Shah R, **Cunha CB, Mylonakis E**. Hydroxychloroquine use in hospitalized patients with COVID-19: An observational matched cohort study (2020) *J Glob Antimicrob Resist* Aug 4;22:842-844. PMID: 32763357
116. **Lonks JR**. Examining the components of effective infection control and prevention. *RI Med J* 2020 Mar2;103(2):17.
117. Crawford AR, Vallande N, **Lonks JR**. MRSA prevalence in preoperative *S. aureus* nasal culture isolates is significantly different from a traditional hospital-wide antibiogram. *RI Med J* 2020 Mar2;103(2):18-20.
118. Steeves S, Vallande N, **Lonks JR**. Safety and nosocomial *Clostridioides difficile* infections. *RI Med J* 2020 Mar2;103(2):21-23.
119. Skrable KA, **Lonks JR**. Antibiotics and nosocomial *Clostridioides difficile*, a retrospective chart review. *RI Med J* 2020 Mar2;103(2):24-27.
120. **Lonks JR**, Nolette E, Cadnum JL, Donskey CJ. Rate of *Clostridioides difficile* culture positivity among hospitalized patients. *RI Med J* 2020 Mar2;103(2):28-30.
121. Tape C, Boyd KM, Aung S, **Lonks JR, Flanigan TP, Rybak NR**. COVID-19 in a patient presenting with syncope and a normal chest x-ray. *RI Med J* 2020 Mar26;103(2):50-51.
122. **Lonks J, Wing EJ**. Lower Respiratory Tract Infections and Tuberculosis. In Wing EJ, Schiffman F (Eds). In *Cecil Essentials of Medicine*. Elsevier, Inc., 2020. 10th edition
123. Choe YJ, Smit MA, **Mermel LA**. Seasonality of respiratory viruses and bacterial pathogens. *Antimicrob Resist Infect Control* 8:125, 2019 <https://doi.org/10.1186/s13756-019-0574-7>.
124. Hoggard JG, Blair RD, Montero M, Moustafa MA, Newman J, Pergola PE, Saucier N, Wheeler CJ III, **Mermel LA**, Ross JR, Beserab AD. Clinical outcomes Associated with the use of the NexSite™ hemodialysis catheter with new exit barrier technology: results from a prospective, observational multi-center registry study. *PLoS One*. 14(10):e0223285. doi: 10.1371/journal.pone.0223285. eCollection 2019.
125. **Mermel LA**. Possible fatal Ciguatera fish poisoning. *RI Med J* 102:56, 2019.
126. de Grooth H-J, Timsit J-F, **Mermel L**, Mimos O, Buetti N, du Cheyron D, Oudemans-van Straaten HM, Parienti J-J, for the 3SITES, CLEAN and DRESSING groups. Validity of

Publications: 10/1/19 – 9/30/20

surrogate endpoints assessing catheter-related infection: evidence from individual- and study-level analyses. *Clin Microbiol Infect* 26:563-571, 2020.

127. Willemsen I, Jefferson J, **Mermel L**, Kluytmans J. Comparison of infection control programs in a Dutch and US hospital using the infection risk scan (IRIS) method. *Am J Infect Control* 48:391-397, 2020.
128. **Mermel LA**. Association of human Eastern Equine Encephalitis with precipitation levels in Massachusetts. *JAMA Netw Open* 2020 Jan 3;3(1):e1920261.
129. Weatherall SL, Chambers AB, **Mermel LA**. Do bacteremic patients with end-stage renal disease have a fever when presenting to the emergency department? A paired, retrospective cohort study. *BMC Emerg Med* 20:2, 2020.
130. Choe YJ, Smit MA, **Mermel LA**. Comparison of common respiratory virus peak incidence among varying age groups in Rhode Island from 2012-2016. *JAMA Netw Open* 2020;3(5):e207041.
131. Berry I, Tuite AR, Salomon A, Drews S, Harris A, Hatchette T, Johnson C, Kwong J, Lojo J, McGeer A, **Mermel L**, Ng V, Fisman DN. Association of influenza activity and environmental conditions with the risk of invasive pneumococcal disease. *JAMA Netw Open* (in press).
132. **Mermel LA**. Sequential use of povidone-iodine and chlorhexidine for cutaneous antisepsis: A systematic review. *Infect Control Hosp Epidemiol* 41:98-10, 2020.
133. Choe YJ, Teevan BE, Smit MA, Quilliam DN, Bandy U, **Mermel LA**. Post-exposure rabies prophylaxis for mass bat exposures: Case series and systematic review. *Zoonoses Public Health* 67:331–341, 2020.
134. Alhazzani W, Hylander Møller M, Arabi YM, Loeb M, Ng Gong M, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundry M, Morgan JS, Kesecioglu J, McGeer A, **Mermel L**, Mammen MJ26, Alexander PE, Arrington A, Centofanti J, Citerio G, Baw B, Memish Z, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med* 46:854-887, 2020 & *Critical Care Med* 48:e440-e469, 2020.
135. **Mermel LA**. How should surveillance systems account for concurrent intravascular catheters? *JAMA Netw Open* 2020 Mar 2;3(3):e200400. (editorial).
136. Parienti JJ, Joint-Lambert O, **Mermel LA**. *Pseudomonas* causing catheter infection in the groin area: a new reason to avoid femoral lines? *Crit Care Med* 48:773-774, 2020 (editorial).
137. **Mermel LA**. Respiratory protection for healthcare workers caring for

Publications: 10/1/19 – 9/30/20

patients with COVID-19 infection (letter). *Infect Control Hosp Epidemiol* 2020 Apr 23:1-8. doi: 10.1017/ice.2020.175. [Epub ahead of print].

138. **Mermel LA.** Keeping hospitals safe during the COVID-19 pandemic: Finding inspiration in a father's credo. *Med Health RI* 103:8, 2020.
139. **Mermel LA.** Disposition of patients with COVID-19 infection whose respiratory specimens remain SARS-CoV-2 PCR-positive. *Infect Control Hosp Epidemiol* 2020 Jun 10:1-8. doi: 10.1017/ice.2020.286. Online ahead of print.
140. Kalligeros M, Karageorgos SA, Shehadeh F, Zacharioudakis IM, **Mylonakis E.** The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: A systematic review and meta-analysis. *Antimicrob Agents Chemother.* 2019 Oct 7;63(12):e01572-19. doi: 10.1128/AAC.01572-19. Epub ahead of print. PMID: 31591125; PMCID: PMC6879222.
141. Kalligeros M, Shehadeh F, Karageorgos SA, Zacharioudakis IM, **Mylonakis E.** MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis. *Burns.* 2019 Nov;45(7):1528-1536. doi: 10.1016/j.burns.2019.05.014. Epub 2019 Jun 13. PMID: 31202530.
142. Tsikala Vafea M, Atalla E, Georgakas J, Shehadeh F, Mylona EK, Kalligeros M, **Mylonakis E.** Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19. *Cell Mol Bioeng.* 2020 Jun 24:1-9. doi: 10.1007/s12195-020-00629-w. Epub ahead of print. PMID: 32837582; PMCID: PMC7314428.
143. Ziakas PD, **Mylonakis E.** Medicare Part D Spending on Drugs Prescribed by Oncologists: Temporal Trends and Regional Variation. *JCO Oncol Pract.* 2020 Aug 19:OP2000165. doi: 10.1200/OP.20.00165. Epub ahead of print. PMID: 32813601.
144. Tori K, Kalligeros M, Nanda A, Shehadeh F, van Aalst R, Chit A, **Mylonakis E.** Association between dementia and psychiatric disorders in long-term care residents: An observational clinical study. *Medicine (Baltimore).* 2020 Jul 31;99(31):e21412. doi: 10.1097/MD.00000000000021412. PMID: 32756140; PMCID: PMC7402876.
145. Khader R, Tharmalingam N, Mishra B, Felix L, Ausubel FM, Kelso MJ, **Mylonakis E.** Characterization of Five Novel Anti-MRSA Compounds Identified Using a Whole-Animal *Caenorhabditis elegans/Galleria mellonella* Sequential-Screening Approach. *Antibiotics (Basel).* 2020 Jul 27;9(8):E449. doi: 10.3390/antibiotics9080449. PMID: 32726955; PMCID: PMC7459823.
146. Shehadeh F, Zacharioudakis IM, Kalligeros M, Mylona EK, Karki T, van Aalst R, Chit A, **Mylonakis E.** Varying Vaccination Rates Among Patients Seeking Care for Acute Respiratory Illness: A Systematic Review and Meta-analysis. *Open Forum Infect Dis.* 2020 Jun 19;7(7):ofaa234. doi: 10.1093/ofid/ofaa234. PMID: 32685605; PMCID: PMC7357453.

Publications: 10/1/19 – 9/30/20

147. Mylona EK, Benitez G, Shehadeh F, Fleury E, Mylonakis SC, Kalligeros M, **Mylonakis E**. The association of obesity with health insurance coverage and demographic characteristics: a statewide cross-sectional study. *Medicine (Baltimore)*. 2020 Jul 2;99(27):e21016. doi: 10.1097/MD.00000000000021016. PMID: 32629722; PMCID: PMC7337412.
148. Kim W, Zou G, Pan W, Fricke N, Faizi HA, Kim SM, Khader R, Li S, Lee K, Escorba I, Vlahovska PM, Gao H, Ausubel FM, **Mylonakis E**. The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant *Staphylococcus aureus*. *mBio*. 2020 Jun 30;11(3):e01140-20. doi: 10.1128/mBio.01140-20. PMID: 32605985; PMCID: PMC7327171.
149. Atalla E, **Mylonakis E**. In MRSA bacteremia, adding a β -lactam to usual care did not improve a composite outcome at 90 days. *Ann Intern Med*. 2020 Jun 16;172(12):JC67. doi: 10.7326/ACPJ202006160-067. PMID: 32539506.
150. Khan AA, Ali A, Tharmalingam N, **Mylonakis E**, Zahra R. First report of mecC gene in clinical methicillin resistant *S. aureus* (MRSA) from tertiary care hospital Islamabad, Pakistan. *J Infect Public Health*. 2020 Jun 6:S1876-0341(20)30483-4. doi: 10.1016/j.jiph.2020.05.017. Epub ahead of print. PMID: 32517997.
151. Tori K, Kalligeros M, Shehadeh F, Khader R, Nanda A, van Aalst R, Chit A, **Mylonakis E**. The process of obtaining informed consent to research in long term care facilities (LTCFs): An Observational Clinical Study. *Medicine (Baltimore)*. 2020 May 22;99(21):e20225. doi: 10.1097/MD.00000000000020225. PMID: 32481294; PMCID: PMC7249968.
152. Tori K, Tansarli GS, Parente DM, Kalligeros M, Ziakas PD, **Mylonakis E**. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model. *Medicine (Baltimore)*. 2020 May;99(20):e20022. doi: 10.1097/MD.00000000000020022. PMID: 32443305; PMCID: PMC7254453.
153. Atalla E, **Mylonakis E**. In utero exposure to systemic antibiotics vs reference penicillins was not linked to congenital malformations. *Ann Intern Med*. 2020 May 19;172(10):JC56. doi: 10.7326/ACPJ202005190-056. PMID: 32422101.
154. Ziakas PD, **Mylonakis E**. Web search popularity, publicity, and utilization of direct oral anticoagulants in the United States, 2008-2018: A STROBE-compliant study. *Medicine (Baltimore)*. 2020 May;99(19):e20005. doi: 10.1097/MD.00000000000020005. PMID: 32384456; PMCID: PMC7220638.
155. Kalligeros M, Zacharioudakis IM, Tansarli GS, Tori K, Shehadeh F, **Mylonakis E**. In-depth analysis of T2Bacteria positive results in patients with concurrent negative blood culture: a case series. *BMC Infect Dis*. 2020 May 7;20(1):326. doi: 10.1186/s12879-020-05049-9. PMID: 32380973; PMCID: PMC7206677.
156. Bose RJC, Tharmalingam N, Garcia Marques FJ, Sukumar UK, Natarajan A, Zeng Y, Robinson E, Bermudez A, Chang E, Habte F, Pitteri SJ, McCarthy JR, Gambhir SS, Massoud TF, **Mylonakis E**, Paulmurugan R. Reconstructed Apoptotic Bodies as Targeted "Nano

Publications: 10/1/19 – 9/30/20

Decoys" to Treat Intracellular Bacterial Infections within Macrophages and Cancer Cells. *ACS Nano*. 2020 May 26;14(5):5818-5835. doi: 10.1021/acsnano.0c00921. Epub 2020 May 4. PMID: 32347709.

157. Cheng AV, Schrank CL, Escobar IE, **Mylonakis E**, Wuest WM. Addition of ethylamines to the phenols of bithionol and synthetic retinoids does not elicit activity in gram-negative bacteria. *Bioorg Med Chem Lett*. 2020 May 1;30(9):127099. doi: 10.1016/j.bmcl.2020.127099. Epub 2020 Mar 9. PMID: 32171615; PMCID: PMC7256867.
158. Volpi C, Shehadeh F, **Mylonakis E**. The role of county-level socioeconomic status on brand-name prescriptions in Medicare part D: A cross-sectional Study. *Medicine (Baltimore)*. 2020 Feb;99(9):e19271. doi: 10.1097/MD.00000000000019271. PMID: 32118735.
159. Kalligeros M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, van Aalst R, Chit A, **Mylonakis E**. Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis. *Vaccine*. 2020 Mar 23;38(14):2893-2903. doi: 10.1016/j.vaccine.2020.02.049. Epub 2020 Feb 27. PMID: 32113808.
160. Mylona EK, Shehadeh F, Fleury E, Kalligeros M, **Mylonakis E**. Neighborhood- Level Analysis on the Impact of Accessibility to Fast Food and Open Green Spaces on the Prevalence of Obesity. *Am J Med*. 2020 Mar;133(3):340-346.e1. doi: 10.1016/j.amjmed.2019.08.024. Epub 2019 Oct 15. PMID: 31626745.
161. Feng J, He L, Xiao X, Chen Z, Chen C, Chu J, Lu S, Li X, **Mylonakis E**, Xi L. Methylcitrate cycle gene MCD is essential for the virulence of *Talaromyces marneffe*i. *Med Mycol*. 2020 Apr 1;58(3):351-361. doi: 10.1093/mmy/myz063. PMID: 31290549.
162. Atalla E, Kalligeros M, Giampaolo G, Mylona EK, Shehadeh F, **Mylonakis E**. Readmissions among Patients with COVID-19. *Int J Clin Pract*. 2020 Sep 7:e13700. doi: 10.1111/ijcp.13700. Epub ahead of print. PMID: 32894801.
163. Shehadeh F, Kalligeros M, Byrd K, Shemin D, **Mylonakis E**, Martin P, **D'Agata EMC**. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. *Sci Rep*. 2020 Aug 31;10(1):14332. doi: 10.1038/s41598-020-71205-5. PMID: 32868869; PMCID: PMC7459301.
164. Tsikala Vafea M, Atalla E, Kalligeros M, Mylona EK, Shehadeh F, **Mylonakis E**. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. *Clin Radiol*. 2020 Aug 12;S0009-9260(20)30313-5. doi: 10.1016/j.crad.2020.07.025. Epub ahead of print. PMID: 32861461; PMCID: PMC7420957.
165. Kim W, Escobar I, Fuchs BB, **Mylonakis E**. Antimicrobial drug discovery against persisters. In: *Persisters*, Springer. 2020
166. Atalla E, Kalligeros M, Giampaolo G, Mylona EK, Shehadeh F, **Mylonakis E**. Readmissions among patients with COVID-19. *Int J Clin Pract*. (in press).

Publications: 10/1/19 – 9/30/20

167. Song SL, Hays SB*, Panton CE*, Mylona EV, Kalligeros M, Shehadeh F, **Mylonakis E**. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: a preliminary study. *Pathogens* (in press).
168. Wambier CG, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, **Nau G**, Herrera S, McCoy J. Androgen sensitivity gateway to COVID-19 disease severity. *Drug Dev Res*. 2020 May 15;10.1002/ddr.21688. doi: 10.1002/ddr.21688. Epub ahead of print. PMID: 32412125; PMCID: PMC7273095.
169. **Nau GJ**, Horzempa J, O'Dee D, Brown MJ, Russo BC, Hernandez A, Dillon ST, Cheng J, Kane LP, Sanker S, Hukriede NA. A predicted *Francisella tularensis* DXD-motif glycosyltransferase blocks immune activation. *Virulence*. 2019 Dec;10(1):643-656. doi: 10.1080/21505594.2019.1631662. PMID: 31314675; PMCID: PMC6650193.
170. **Neill MA**. Other Pathogenic Vibrios. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 9th Ed. R. Dolin, JE Bennett, MJ Blaser. Ch. 215, pg 2645-49; Elsevier, Philadelphia, PA; 2019.
171. Dunham K, McDonald J, Yousaf A, Barocas J, **Neill MA**, Noska A, **Flanigan TP**. Healthcare Providers' Views on HCV Testing and Counseling Among Sexual Partners of Hepatitis C Infected Persons. (in press).
172. Lattère P-F, Levy M, Wittebole X, Dugernier T, Francois B, **Opal SM**. Should soluble thrombomodulin be further tested as a therapy for septic shock? *Anesthesia Critical Care and Pain Medicine*. 2019; 38(5), 419-421.
173. Edgar R, TarrioM, Maislin G, Chiguang F, **Opal SM**, Cross AS, Kaempfer R, Shirvan A. Treatment with one dose of reltecimod is superior to two doses in mouse models of lethal infection. *International Journal of Peptide Research* 2019; 19(4): doi.org/10.1007/s10989-019-09974-5.
174. McMullan P, White A, Coker O, Hill S, **Opal SM**, Rogers G. Antimicrobial efficacy of continuous-low irradiance phototherapy against multidrug resistant organisms. *Scars, Burns and Healing*. 2020 (in press)
175. Fedson DS, **Opal, SM**, Rordam OM. Hiding in plain sight: An approach to treating patients with severe COVID-19 infection, *MBio* 2020;11(2) e00398-20.
176. Hotchkiss R, **Opal SM**. Activating immunity to fight a foe: a new path. *New England Journal of Medicine*. 2020; 382:1270-1272
177. Tannous A, Levinson S, Bolongnese J, **Opal SM**, DiNubile M. Safety and pharmacokinetics of recombinant human plasma gelsolin in patients hospitalized for non-severe community-acquired pneumonia. *Antimicrobial Agents and Chemotherapy* 2020 (in Press)

Publications: 10/1/19 – 9/30/20

178. Tang X, Lu H, **Ramratnam B**. Neurotoxicity of HIV-1 Tat is attributed to its penetrating property. *Sci Rep*. 2020 Aug 19;10(1):14002. doi: 10.1038/s41598-020-70950-x. PMID: 32814783; PMCID: PMC7438513.
179. Tasker C, Pizutelli V, Lo Y, **Ramratnam B**, Roche NE, Chang TL. Depot medroxyprogesterone acetate administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa. *AIDS*. 2020 Apr 1;34(5):729-735. doi: 10.1097/QAD.0000000000002475. PMID: 31972606; PMCID: PMC7337252.
180. Cheng Y, Pereira M, Raukar NP, Reagan JL, Quesenberry M, Goldberg L, Borgovan T, LaFrance Jr WC, Dooner M, Deregibus M, Camussi G, **Ramratnam B**, Quesenberry P. Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head trauma. *Neural Regen Res*. 2020 Apr;15(4):676-681. doi: 10.4103/1673-5374.266924. PMID: 31638091; PMCID: PMC6975135.
181. Peterson M, Macmadu A, Truong AQ, **Rich J**, Pognon K, Lurie M, Clarke JG, Brinkley-Rubinstein L. Pre-exposure prophylaxis awareness and interest among participants in a medications for addiction treatment program in a unified jail and prison setting in Rhode Island. *J Subst Abuse Treat*. 2019 Nov;106:73-78. doi: 10.1016/j.jsat.2019.08.015. Epub 2019 Aug 28. PMID:31540614
182. Bernstein MH, Magill M, Weiss AP, Kaptchuk TJ, Blease C, Kirsch I, **Rich JD**, Becker SJ, Mach S, Beaudoin FL. Are Conditioned Open Placebos Feasible as an Adjunctive Treatment to Opioids? Results from a Single-Group Dose-Extender Pilot Study with Acute Pain Patients. *Psychother Psychosom*. 2019;88(6):380-382. doi: 10.1159/000503038. Epub 2019 Sep 27. No abstract available. PMID:31563914 PMCID: PMC6868304 [Available on 2020-09-27]
183. Brinkley-Rubinstein L, Peterson M, Clarke J, Macmadu A, Truong A, Pognon K, Parker M, Marshall BDL, Green T, Martin R, Stein L, **Rich JD**. The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. *Drug Alcohol Depend*. 2019 Dec 1;205:107514. doi: 10.1016/j.drugalcdep.2019.06.016. Epub 2019 Oct 7. PMID:31614328
184. Yedinak JL, Goedel WC, Paull K, Lebeau R, Krieger MS, Thompson C, Buchanan AL, Coderre T, Boss R, **Rich JD**, Marshall BDL. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. *PLoS Med*. 2019 Nov 19;16(11):e1002963. doi: 10.1371/journal.pmed.1002963. eCollection 2019 Nov. PMID:31743335 PMCID:PMC6863520
185. Peterson M, Macmadu A, Truong AQ, **Rich J**, Pognon K, Lurie M, Clarke JG, Brinkley-Rubinstein L. Pre-exposure prophylaxis awareness and interest among participants in a medications for addiction treatment program in a unified jail and prison setting in Rhode Island. *J Subst Abuse Treat*. 2019 Nov;106:73-78. doi: 10.1016/j.jsat.2019.08.015. Epub 2019 Aug 28. PMID: 31540614.

Publications: 10/1/19 – 9/30/20

186. Brinkley-Rubinstein L, Allen SA, **Rich JD**. Incarceration and the health of detained children. *Lancet Public Health*. 2020 Feb;5(2):e76-e77. doi: 10.1016/S2468-2667(19)30250-6. Epub 2020 Jan 16. No abstract available. PMID:31954436
187. Skarha J, Peterson M, **Rich JD**, Dosa D. An Overlooked Crisis: Extreme Temperature Exposures in Incarceration Settings. *Am J Public Health*. 2020 Jan;110(S1):S41-S42. doi: 10.2105/AJPH.2019.305453. No abstract available. PMID:31967879 PMCID:PMC6987924
188. Goldman JE, Samuels EA, **Rich JD**, Marshall BDL. Correlates of death during outpatient treatment for opioid use disorder: A national study. *J Subst Abuse Treat*. 2020 May;112:76-85. doi: 10.1016/j.jsat.2020.01.003. Epub 2020 Jan 15. PMID: 32199549
189. Macmadu A, Goedel WC, Adams JW, Brinkley-Rubinstein L, Green TC, Clarke JG, Martin RA, **Rich JD**, Marshall BDL. Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails. *Drug and Alcohol Dependence*, Volume 208, 2020, 107858, ISSN 0376-8716, <https://doi.org/10.1016/j.drugalcdep.2020.107858>.
190. Carroll JJ, **Rich JD**, Green TC. The protective effect of trusted dealers against opioid overdose in the U.S. *Int J Drug Policy*. 2020 Mar 3;78:102695. doi: 10.1016/j.drugpo.2020.102695. [Epub ahead of print] PMID:32143185
191. Truong AQ, Patil S, **Rich JD**. Prescribers and Naloxone Pharmacy Claims. *J Gen Intern Med*. 2020 Mar 19. doi: 10.1007/s11606-020-05760-y. [Epub ahead of print] No abstract available. PMID:32193816
192. Akiyama MJ, Spaulding AC, **Rich JD**. Flattening the Curve for Incarcerated Populations - Covid-19 in Jails and Prisons. *N Engl J Med*. 2020 Apr 2. doi: 10.1056/NEJMp2005687. [Epub ahead of print] No abstract available. PMID: 32240582
193. Langdon KJ, Ramsey S, Scherzer C, Carey K, Ranney ML, **Rich J**. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder. *Addict Sci Clin Pract*. 2020;15(1):16. Published 2020 Apr 29. doi:10.1186/s13722-020-00189-4 PMID: 32349790 PMCID: [PMC7191734](https://pubmed.ncbi.nlm.nih.gov/PMC7191734/)
194. Stone, Andrew, Carroll JJ, **Rich JD**, Green TC, One year of Methadone Maintenance Treatment in a Fentanyl Endemic Area: Safety, Repeated Exposure, Retention, and Remission. *Journal of Substance Abuse Treatment*, Volume 115, 2020, 108031, ISSN 0740-5472. <https://doi.org/10.1016/j.jsat.2020.108031>.
195. Winetsky D, Fox A, Nijhawan A, **Rich JD**. Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System. *Infect Dis Clin North Am*. 2020 Sep;34(3):585-603. doi: 10.1016/j.idc.2020.06.012. PMID: 32782103; PMCID: PMC7433020.
196. Macmadu A, Adams JW, Bessey SE, Brinkley-Rubinstein L, Martin RA, Clarke JG, Green TC, **Rich JD**, Marshall BDL. Optimizing the impact of medications for opioid use disorder

Publications: 10/1/19 – 9/30/20

at release from prison and jail settings: A microsimulation modeling study. *Int J Drug Policy*. 2020 Jul 8;102841. doi: 10.1016/j.drugpo.2020.102841. Epub ahead of print. PMID: 32712165.

197. Puing AG, Li X, **Rich J**, Nijhawan AE. Emergency department utilization by people living with HIV released from jail in the US South. *Health Justice*. 2020 Jun 27;8(1):16. doi: 10.1186/s40352-020-00118-2. PMID: 32594269; PMCID: PMC7321540.
198. Wakeman SE, Green TC, **Rich J**. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. *Nat Med*. 2020 Jun;26(6):819-820. doi: 10.1038/s41591-020-0898-0. PMID: 32555514.
199. Irvine M, Coombs D, Skarha J, Del Pozo B, **Rich J**, Taxman F, Green TC. Modeling COVID-19 and Its Impacts on U.S. Immigration and Customs Enforcement (ICE) Detention Facilities, 2020. *J Urban Health*. 2020 Aug;97(4):439-447. doi: 10.1007/s11524-020-00441-x. PMID: 32415422; PMCID: PMC7228433.
200. Macmadu A, Adams JW, Bessey SE, Brinkley-Rubinstein L, Martin RA, Clarke JG, Green TC, **Rich JD**, Marshall BDL. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study. *Int J Drug Policy*. 2020 Jul 8;102841. doi: 10.1016/j.drugpo.2020.102841. Epub ahead of print. PMID: 32712165.
201. Del Pozo B, Beletsky L, **Rich JD**. COVID-19 as a Frying Pan: The Promise and Perils of Pandemic-Driven Reform. *J Addict Med*. 2020 Jun 16. doi: 10.1097/ADM.0000000000000703. Epub ahead of print. PMID: 32604133.
202. Salisbury-Afshar EM, **Rich JD**, Adashi EY. Vulnerable Populations: Weathering the Pandemic Storm. *Am J Prev Med*. 2020 Jun;58(6):892-894. doi: 10.1016/j.amepre.2020.04.002. Epub 2020 Apr 22. PMID: 32371018; PMCID: PMC7174188.
203. Lerner AH, Shu L, **Rogers R**, **Farmakiotis D**. A kidney transplant recipient with nausea, vomiting, and diarrhea after a recent COVID-19 exposure. *Am J Transplant*. 2020 Sep;20(9):2618-2620. doi: 10.1111/ajt.16184. PMID: 32862559.
204. **Rogers R**, O'Brien T, Aridi J, **Beckwith CG**. The COVID-19 Diagnostic Dilemma: a Clinician's Perspective. *J Clin Microbiol*. 2020 Jul 23;58(8):e01287-20. doi: 10.1128/JCM.01287-20. PMID: 32703894; PMCID: PMC7383561.
205. **Rogers R**, Saharia K, Chandorkar A, Weiss ZF, Vieira K, Koo S, **Farmakiotis D**. Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. *BMC Infect Dis*. 2020 Jan 17;20(1):58. doi: 10.1186/s12879-020-4787-4. Erratum in: *BMC Infect Dis*. 2020 Feb 11;20(1):122. PMID: 31952516; PMCID: PMC6969482.

Publications: 10/1/19 – 9/30/20

206. **Rogers R, Farmakiotis D.** Infections in the Immunocompromised Host. In: Ivor B, Griggs R, Wing EJ, Figgs GJ (Editors). *Andreoli and Carpenter's Cecil Essentials of Medicine*, 10th Edition. Elsevier. In press.
207. Aibana O, Dauria E, Kiriazova T, Makarenko O, Bachmaha M, **Rybak N, Flanigan TP**, Petrenko V, Becker AE, Murray MB. Patients' perspectives of tuberculosis treatment challenges and barriers to treatment adherence in Ukraine: a qualitative study. (2020) *BMJ Open*. Feb 2;10(1): e032027. PMID: 32014870. PMCID: PMC7044979
208. Sereda Y, Kiriazova T, Makarenko O, Carroll JJ, **Rybak N**, Chybisov A, Bendiks S, Idrisov B, Dutta A, **Gillian FS**, Samet JH, **Flanigan T**, Lunze K. Stigma and quality of co-located care for HIV-positive people in addiction treatment in Ukraine: a cross-sectional study. (2020) *J Int AIDS Soc*. May 25; 23: e25492. doi: 10.1002/jia2.25492. PMID: 32372534. PMCID: PMC7201176
209. Chiang SS, Dolynska M, **Rybak NR**, et al. Clinical manifestations and epidemiology of adolescent tuberculosis in Ukraine. *ERJ Open Res* 2020; 6: 00308-2020 [https://doi.org/10.1183/23120541.00308-2020].
210. **Sanchez MC.** Hepatitis A and B Vaccination in the United States. *R I Med J* (2013). 2020 Aug 3;103(6):44-46. PMID: 32752566.
211. Collins JP, Friedman CR, Birhane MG, Karp BE, Osinski A, Montgomery MW, Thomas D, Barkley J, **Sanchez MC**, Hanna S, Adediran AA, Chen JC, Caidi H, Francois Watkins L. Evidence of Failure of Oral Third-Generation Cephalosporin Treatment for *Shigella sonnei* Infection. *Open Forum Infect Dis*. 2020 Apr 18;7(4):ofaa113. doi: 10.1093/ofid/ofaa113. PMID: 32341933; PMCID: PMC7175969.
212. Kalligeros M, **Tashima KT**, Mylona E, **Rybak NR, Flanigan TP, Farmakiotis D, Beckwith CG, Sanchez M, Neill M, Johnson JE, Garland JM**, Aung SN, Byrd KM, O'Brien T, Pandita A, Aridi J, Macias-Gil R, **Larkin J**, Shehadeh F, **Mylonakis E**. Remdesivir use in hospitalized patients with severe COVID-19: A single-center experience compared to supportive care. *Open Forum Infect Dis*; accepted for publication.
213. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJusis E, Lai MT, Rodgers A, Pupinacci L, Kumar s, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. **Tashima K**, 1 of 125 Collaborators. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomized, double-blind, non-inferiority, phase 3 trial (2020). *Lancet HIV* 2020 Jan7(1): e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. PMID:31740348.
214. Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, Sen Gupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Munoz J, Mullane KM, Marty FM, **Tashima KT**, Diaz G, Subramanian A, for the GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in

Publications: 10/1/19 – 9/30/20

patients with severe COVID-19. (2020) *N Engl J Med* 2020 May 27. doi:10.1056/NEJMoa2015301. [Epub ahead of print] PMID:32459919.

215. Rana AI, Castillo-Mancilla JR, **Tashima KT**, Landowitz RL. Advances in long-acting agents for the treatment of HIV infection. *Drugs* 2020 Apr;80(6):535-45. Doi: 10.1007/s40265-020-01284-1. PMID:32180205.
216. Gandhi RT, **Tashima KT**, Smeaton LM, Vu V, Ritz J, Andrade A, Eron JJ, Hogg E, Fichtenbaum CJ. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS). *J Infect Dis* 2020 Apr 7;221(9): 1407-15. doi: 10.1093/infdis/jiz281. PMID:31135883.
217. Neilan TG, Nguyen K, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadella M, Drobni ZD, Nelson MD, Burdo TH, Schalkwyk, MV, Sax PE, Skiest DJ, **Tashima KT**, Landovitz RJ, Daar E, Wurcel, AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaud H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial steatosis among antiretroviral therapy-treated people with human immunodeficiency virus participating in the REPRIEVE trial. *J Infect Dis* 2020 July 9;222 (Suppl 1) S63-S69, doi: 10.1093/infdis/jiaa245, PMID: 32645158.
218. **Touzard-Romo F**, Tape C, **Lonks JR**. Co-infection with SARS-CoV-2 and Human Metapneumovirus. (2020) *R I Med J*. 2020 Mar 19; 103(2): 75-6. PMID: 32192233
219. **Tunkel AR**. The Dean in the ICU. *The Pharos* Autumn 2019:30-34.
220. **Tunkel AR**, Baron EL, Buch KA, Marty FM, Martinez-Lage M. Case 31-2019: A 45-year-old woman with headache and somnolence. *Case Records of the Massachusetts General Hospital*. *N Engl J Med* 2019; 381:1459-1470.
221. Morgan HK, Mejicano GC, Skochelak S, Lomis K, Hawkins R, **Tunkel AR**, Nelson EA, Henderson D, Shelgikar AV, Stanten SA. A responsible educational handover: Improving communication to improve learning. *Acad Med* 2020;95:194-199. DOI: 10.1097/ACM.0000000000002915.
222. Flynn MM, Monteiro K, George P, **Tunkel AR**. Assessing food insecurity in medical students. *Family Med* 2020;52:512-513.
223. Sobel JD, Bush LM, **Tunkel AR**. Donald Kaye: 1931-2020, in memoriam. *Clin Infect Dis* DOI: 10.1093/cid/ciaa1159.
224. Hasbun R, **Tunkel AR**. Approach to the patient with central nervous system infection. In: *Principles and Practice of Infectious Diseases*, 9th ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. 2020:1176-1182.

Publications: 10/1/19 – 9/30/20

225. Hasbun R, van de Beek D, Brouwer MC, **Tunkel AR**. Acute meningitis. In: Principles and Practice of Infectious Diseases, 9th ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. 2020:1183-1219.
226. Gea-Banacloche JC, **Tunkel AR**. Brain abscess. In: Principles and Practice of Infectious Diseases, 9th ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. 2020:1248-1261.
227. **Tunkel AR**. Subdural empyema, epidural abscess, and suppurative intracranial thrombophlebitis. In: Principles and Practice of Infectious Diseases, 9th ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. 2020:1262-1271.
228. Bhimraj A, **Tunkel AR**. Cerebrospinal fluid shunt and drain infections. In: Principles and Practice of Infectious Diseases, 9th ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. 2020:1272-1281.
229. Borkan J, George P, **Tunkel AR**. In reply to Weissman, The Perils of Curricular Change. *Acad Med* 2019;94:746-747.
230. Green E, George P, **Tunkel AR**. One size does not fit all: flexible scheduling of USMLE Step 1 as a component of competency-based medical education. *Acad Med* 2020;95:665.
231. Panza E, **Wing EJ**, Wing R. Behavioral weight loss: A Promising Treatment for Obesity in Adults with HIV. (2020) *AIDS Behav.* Apr;24(4): 1085-91. PMID: 31456199. PMCID: PMC7044054
232. Bungiro R, **Wing E**. Host Defenses against Infection. Wing EJ, Schiffman F (Eds). In *Cecil Essentials of Medicine*. Elsevier, Inc., 2020. 10th edition
233. **Wing EJ**. Appendix: Coronavirus Disease 2019 (COVID 19). In *Cecil Essentials of Medicine*. Elsevier Inc. 2020. 10th Edition.
234. Wing RR, Becofshy K, **Wing EJ**, McCaffrey J, Boudreau M, Evans EW, Unick J. Behavioral and cardiovascular effect of a behavioral weight loss program for people living with HIV. (2020) *AIDS Behav.* Apr;24(4):1032-104. PMID31004243
235. **Garland JM**, Levinson A, **Wing EJ**. Care of Critically ill patients with Human Immunodeficiency Virus. (2020) *Ann Am Thorac Soc.* Jun;17(6): 659-69. PMID:32216642
236. **Lonks J**, **Wing EJ**. Lower Respiratory Tract Infections and Tuberculosis. In Wing EJ, Schiffman F (Eds). In *Cecil Essentials of Medicine*. Elsevier, Inc., 2020. 10th edition
237. **Garland JM**, **Flanigan T**, **Wing EJ**. Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. Wing EJ, Schiffman F (Eds). In *Cecil Essentials of Medicine*. Elsevier, Inc., 2020. 10th edition